Denali Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Denali Therapeutics's estimated annual revenue is currently $353M per year.
- Denali Therapeutics received $130.0M in venture funding in August 2016.
- Denali Therapeutics's estimated revenue per employee is $693,438
- Denali Therapeutics's total funding is $347M.
- Denali Therapeutics's current valuation is $4.3B. (January 2022)
- Denali Therapeutics has 509 Employees.
- Denali Therapeutics grew their employee count by 12% last year.
Denali Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Denali Therapeutics?
Denali Therapeutics Inc. (Denali) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
Denali Therapeutics News
For Denali Therapeutics Inc.The Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently...
Brokerages expect Denali Therapeutics Inc. (NASDAQ:DNLI Get Rating) to post sales of $26.10 million for the current fiscal quarter,...
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of Buy from Brokerages. Posted by admin on Apr 16th, 2022.
Denali to present results from Phase 1 healthy volunteer study of EIF2B activator DNL343 Sanofi to present Phase 2 study plans in ALS for RIPK1 inhibitor SAR443820 Denali to host analyst and investor webinar on October 6, at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 29, 2021 (GL ...
GSA Capital Partners LLP increased its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 174.3% in the second quarter, according to its ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Denali Therapeutics Funding